{
  "resourceType": "StructureDefinition",
  "id": "shr-oncology-NuclearPleomorphismScore-model",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n  <p><b>BC NuclearPleomorphismScore Logical Model</b></p>\n  <p>The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.</p>\n</div>"
  },
  "url": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-oncology-NuclearPleomorphismScore-model",
  "identifier": [
    {
      "system": "http://hl7.org/fhir/us/breastcancer",
      "value": "shr.oncology.NuclearPleomorphismScore"
    }
  ],
  "name": "NuclearPleomorphismScoreModel",
  "title": "BC NuclearPleomorphismScore Logical Model",
  "status": "draft",
  "date": "2018-08-07",
  "publisher": "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/cic/index.cfm"
        }
      ]
    }
  ],
  "description": "The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
  "keyword": [
    {
      "system": "http://loinc.org",
      "code": "44645-0",
      "display": "Nuclear pleomorphism in Breast tumor Qualitative by Nottingham"
    }
  ],
  "kind": "logical",
  "abstract": false,
  "type": "shr-oncology-NuclearPleomorphismScore-model",
  "baseDefinition": "http://hl7.org/fhir/StructureDefinition/Element",
  "derivation": "specialization",
  "snapshot": {
    "element": [
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model",
        "path": "shr-oncology-NuclearPleomorphismScore-model",
        "definition": "The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "min": 0,
        "max": "*",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model",
          "min": 0,
          "max": "*"
        },
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.value",
        "path": "shr-oncology-NuclearPleomorphismScore-model.value",
        "short": "Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "definition": "Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.value",
          "min": 1,
          "max": "1"
        },
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/shr-oncology-NuclearPleomorphismScoreVS"
          }
        }
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
        "path": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
        "short": "The concept representing the finding or action that is the topic of the statement.",
        "definition": "The concept representing the finding or action that is the topic of the statement.\n\nFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-TopicCode-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
        "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
        "short": "Reason that a value associated with a test or other finding is missing.",
        "definition": "Reason that a value associated with a test or other finding is missing.",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-context-ExceptionValue-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue.value",
        "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue.value",
        "short": "Code representing reason that a value associated with a test or other finding is missing.",
        "definition": "Code representing reason that a value associated with a test or other finding is missing.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "base": {
          "path": "cimi-context-ExceptionValue-model.value",
          "min": 1,
          "max": "1"
        },
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/shr-oncology-NottinghamComponentNullVS"
          }
        }
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
        "path": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0420833"
          }
        ],
        "short": "A clinical interpretation of a finding (applies to both assertions and observation).",
        "definition": "A clinical interpretation of a finding (applies to both assertions and observation).",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-context-Interpretation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
        "path": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0883335"
          }
        ],
        "short": "The usual or acceptable range for a test result.",
        "definition": "The usual or acceptable range for a test result.",
        "min": 0,
        "max": "0",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
          "min": 0,
          "max": "0"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      }
    ]
  },
  "differential": {
    "element": [
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model",
        "path": "shr-oncology-NuclearPleomorphismScore-model",
        "definition": "The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "min": 0,
        "max": "*",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model",
          "min": 0,
          "max": "*"
        },
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.value",
        "path": "shr-oncology-NuclearPleomorphismScore-model.value",
        "short": "Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "definition": "Code representing the degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.value",
          "min": 1,
          "max": "1"
        },
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/shr-oncology-NuclearPleomorphismScoreVS"
          }
        }
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
        "path": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
        "short": "The concept representing the finding or action that is the topic of the statement.",
        "definition": "The concept representing the finding or action that is the topic of the statement.\n\nFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.topicCode",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-TopicCode-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
        "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
        "short": "Reason that a value associated with a test or other finding is missing.",
        "definition": "Reason that a value associated with a test or other finding is missing.",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-context-ExceptionValue-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue.value",
        "path": "shr-oncology-NuclearPleomorphismScore-model.exceptionValue.value",
        "short": "Code representing reason that a value associated with a test or other finding is missing.",
        "definition": "Code representing reason that a value associated with a test or other finding is missing.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "base": {
          "path": "cimi-context-ExceptionValue-model.value",
          "min": 1,
          "max": "1"
        },
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/shr-oncology-NottinghamComponentNullVS"
          }
        }
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
        "path": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0420833"
          }
        ],
        "short": "A clinical interpretation of a finding (applies to both assertions and observation).",
        "definition": "A clinical interpretation of a finding (applies to both assertions and observation).",
        "min": 0,
        "max": "1",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.interpretation",
          "min": 0,
          "max": "1"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-context-Interpretation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
        "path": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0883335"
          }
        ],
        "short": "The usual or acceptable range for a test result.",
        "definition": "The usual or acceptable range for a test result.",
        "min": 0,
        "max": "0",
        "base": {
          "path": "shr-oncology-NuclearPleomorphismScore-model.referenceRange",
          "min": 0,
          "max": "0"
        },
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      }
    ]
  }
}